DESCOVY Drug Patent Profile

When do Descovy patents expire, and what generic alternatives are available?

Descovy is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and nineteen patent family members in forty-five countries.

The generic ingredient in DESCOVY is emtricitabine; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Descovy

A generic version of DESCOVY was approved as emtricitabine; tenofovir alafenamide fumarate by MACLEODS PHARMS LTD on April 7^th, 2026.

Summary for DESCOVY

International Patents:	119
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	19
Patent Applications:	263
Drug Prices:	Drug price information for DESCOVY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DESCOVY
What excipients (inactive ingredients) are in DESCOVY?	DESCOVY excipients list
DailyMed Link:	DESCOVY at DailyMed

See drug prices for DESCOVY

Recent Clinical Trials for DESCOVY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Drug Abuse (NIDA)	PHASE1
Johns Hopkins University	PHASE1
National University Hospital, Singapore	PHASE1

See all DESCOVY clinical trials

Pharmacology for DESCOVY

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for DESCOVY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DESCOVY	Tablets	emtricitabine; tenofovir alafenamide fumarate	120 mg/15 mg	208215	1	2022-10-31
DESCOVY	Tablets	emtricitabine; tenofovir alafenamide fumarate	200 mg/25 mg	208215	6	2019-11-05

US Patents and Regulatory Information for DESCOVY

DESCOVY is protected by six US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-002	Jan 7, 2022		RX	Yes	No			Y
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-002	Jan 7, 2022		RX	Yes	No
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-001	Apr 4, 2016	AB	RX	Yes	Yes
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-001	Apr 4, 2016	AB	RX	Yes	Yes			Y
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-002	Jan 7, 2022		RX	Yes	No					Y
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-002	Jan 7, 2022		RX	Yes	No					Y

Expired US Patents for DESCOVY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-001	Apr 4, 2016

International Patents for DESCOVY

When does loss-of-exclusivity occur for DESCOVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

India

Israel

Japan

Lithuania

Mexico

Moldova, Republic of

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DESCOVY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016287500
Australia	2019210558
Australia	2021202009
Brazil	112017027843
Canada	2990210
Chile	2017003320

Supplementary Protection Certificates for DESCOVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1301519	2016/014	Ireland		PRODUCT NAME: TENOFOVIR ALAFENAMIDE OR A SALT OR SOLVATE THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061/001-EU/1/15/1061/002 20151119
0513200	91073	Luxembourg		91073, EXPIRES: 20160131
0513200	300148	Netherlands		300148, 20110131, EXPIRES: 20160130
0513200	SPC/GB04/016	United Kingdom		PRODUCT NAME: EMTRICITABINE OR SALTS AND ESTERS THEREOF; REGISTERED: UK EU/1/03/261/001 20031024; UK EU/1/03/261/002 20031024; UK EU/1/03/261/003 20031024
0513200	SZ 7/2004	Austria
0513200	C00513200/01	Switzerland		PRODUCT NAME: EMTRICITABINE; REGISTRATION NUMBER/DATE: SWISSMEDIC 56880 25.10.2004

DESCOVY (emtricitabine/tenofovir alafenamide) market dynamics and financial trajectory: pricing, volume drivers, exclusivity and generic risk, and revenue outlook

Last updated: July 21, 2026

DESCOVY revenue has been driven by sustained HIV pre-exposure prophylaxis (PrEP) demand in the US and select international markets, with category expansion offset by payor pressure, antiretroviral competition, and the need for ongoing label- and guideline-driven uptake. Near-term financial trajectory hinges on (1) PrEP persistence and formulary position, (2) mix shift between PrEP and HIV treatment use cases, (3) share gains and losses versus Truvada and generic competitors in PrEP programs, and (4) patent and regulatory risk for tenofovir alafenamide fixed-dose combinations in the US.

How is DESCOVY priced and what drives US net sales volatility?

US net sales for DESCOVY are sensitive to launch-year base pricing, annual wholesaler/chargeback dynamics, and shifting reimbursement. In branded PrEP, revenue volatility is typically driven by (i) formulary changes at PBMs and state programs, (ii) patient persistence with daily oral regimens, and (iii) channel inventory normalization following demand spikes.

What are the primary net sales drivers for DESCOVY?

• PrEP demand and persistence: Once a patient starts, continued daily dosing tends to support steady repeat prescriptions, making discontinuation rates a key factor.
• Managed care coverage: PBM coverage and state Medicaid preferred drug lists affect whether prescribers can write DESCOVY without prior authorization or step therapy.
• Competitive category pricing: Competition from branded alternatives and generic tenofovir disoproxil fumarate (TDF) regimens pressures net pricing.
• Patient mix: PrEP-only use differs from people treated as part of HIV management (where clinical status, adherence and regimen selection can differ).

Which payor and channel effects matter most?

• Contracting/rebates: Net price can move with retrospective rebates, patient assistance uptake, and channel contract terms.
• Inventory and buying patterns: Wholesaler pull-forward can temporarily lift reported shipments and later create catch-down.
• Public program procurement: US state and federal PrEP program contracting can shift volume and timing.

What market share and competitive forces shape DESCOVY’s revenue trajectory?

DESCOVY competes in the oral PrEP space against fixed-dose TDF/FTC regimens (most notably generic and brand Truvada historically) and other HIV prevention strategies. Market share is primarily a function of guideline preference, renal safety perceptions, and formulary placement.

How does DESCOVY compete versus Truvada and generics?

• Clinical differentiation: DESCOVY is tenofovir alafenamide/emtricitabine (TAF/FTC), which is often positioned on renal and bone safety versus TDF/FTC for appropriate patient groups.
• Formulary optics: PBMs frequently anchor preferred status to net cost per day and rebate structure; even with clinical differentiation, higher branded acquisition cost can force prior auth.
• Generic availability for TDF/FTC: Generic TDF/FTC can compress PrEP budget and create substitution pressure in real-world prescribing.

What competitive dynamics influence prescriptions in practice?

• Prior authorization and step edits can delay starts or switch patients to TDF/FTC.
• Special population prescribing: Renal impairment history or bone density concerns can favor TAF-based selection where coverage allows.
• Switching behavior: Switching from TDF/FTC to TAF/FTC can occur with clinician and payor approvals, supporting share gains in some payer segments.

How have HIV prevention guidelines and patient selection affected DESCOVY adoption?

DESCOVY’s uptake depends on who is eligible and how clinicians interpret label restrictions and guideline updates for PrEP. Adoption tends to track guideline alignment and prescriber comfort with renal and bone endpoints.

How does patient selection affect growth?

• Renal and bone-risk targeting: Clinicians may select DESCOVY when renal or bone concerns exist, subject to coverage.
• Real-world persistence: Daily oral adherence and follow-up testing protocols influence continuation rates.
• Clinic-based contracting: High-volume sexual health clinics and community programs can drive regional share if purchasing and reimbursement are favorable.

What label constraints influence adoption?

DESCOVY PrEP labeling has historically excluded certain populations from indication scope, which limits addressable volume compared with broader TDF/FTC indications. Any change in label scope or guideline interpretation can alter the near-term TAM.

What is the financial trajectory of DESCOVY across major geographies?

Global revenue is shaped by US-centric reporting, with international sales dependent on local approvals, reimbursement frameworks, and government procurement.

How does US performance compare with ex-US dynamics?

• US is the demand and pricing anchor: US net sales are generally more resilient to international pricing shocks due to contracting structure and guideline-driven prescribing.
• Ex-US tends to be procurement-driven: Where health systems bulk-buy, timing and tender cycles drive quarterly sales variability.
• Pricing pressure in mature markets: Local generic penetration for older regimens can pressure branded TAF/FTC pricing over time.

When does DESCOVY lose exclusivity in the US, and what does that mean for revenue risk?

Revenue risk in the US is tied to patent and regulatory exclusivity rather than “calendar time” alone. Branded HIV combinations typically face generic pressure through Paragraph IV (PIV) challenges once Orange Book-listed patents near expiry.

What exclusivity or patent cliffs matter for generic entry risk?

• US patent expiry: Determines when ANDA or 505(b)(2) pathways can support generic or biosimilar-adjacent competition.
• HIV combination “regimen” switching: Even before hard expiry, payers can increase substitution if competitors appear on formularies.

What is the generic entry risk profile?

For DESCOVY specifically, financial downside risk increases when:

• orange book-listed patents covering composition, method, or formulation near expiry, and
• ANDA applicants file PIV certifications enabling incentives to launch at risk (or post-settlement at defined timelines).

What patents protect DESCOVY and which are most likely to be targeted by Paragraph IV?

DESCOVY contains emtricitabine and tenofovir alafenamide in a fixed-dose combination. Generic entry typically depends on patent coverage around:

1. the drug substance(s) and their compositions,
2. the fixed-dose formulation,
3. and method-of-use or dosing/regimen claims for HIV treatment or PrEP.

Patent estate mapping: how infringement theories usually split

• Composition-of-matter patents: Often hardest for challengers to bypass.
• Formulation and tablet-process patents: Can create non-infringement workarounds but raise manufacturing/IP barriers.
• Method-of-use patents: May be targeted if the ANDA or 505(b)(2) carve-out strategy can avoid direct inducement for a protected use.

How strong is the likely DESCOVY patent estate?

In HIV combination drugs, estates often remain active through multiple patent families. Financially, that can delay material erosion until late in the exclusivity chain, although payers may still shift patient mix earlier.

What is the Orange Book status of DESCOVY and how many ANDA pathways are relevant?

Orange Book listings determine the “hardness” of the IP wall for generic approval and launch. The practical revenue model for branded HIV combinations assumes:

• multiple Orange Book-listed patents,
• at least some that can be challenged,
• and potential settlements that delay launch.

How Orange Book status translates into commercial timelines

• If multiple patents are listed with staggered expiries: generic launches can be delayed or split (partial approvals, delayed marketing).
• If settlements occur: launch dates shift to settlement-defined triggers independent of absolute patent expiry.

What patent litigation affects DESCOVY and how do settlements change launch dates?

Patent litigation in HIV drug combinations usually involves:

• ANDA PIV notices and infringement claims in district court,
• possible stays pending USPTO processes,
• and settlement agreements that define “at-risk” launch dates and carve-outs.

How litigation outcomes typically impact revenue

• If patents are upheld: challengers exit or settle later, protecting branded cash flows.
• If invalidity is found for key patents: launch timing accelerates and net pricing collapses.
• If settlements are reached: branded revenue follows settlement calendars until generic entry.

What formulations and manufacturing patents could block or delay generic DESCOVY?

Even when composition patents are cleared, formulation and manufacturing method patents can delay generic competition by:

• limiting ability to meet claim requirements for bioequivalence without infringing,
• requiring process changes to avoid manufacturing infringement,
• and creating regulatory chemistry-manufacturing-control (CMC) hurdles.

What manufacturing/IP barriers matter most in practice?

• Tablet formulation and excipient composition: Can be protected as a formulation invention.
• Solid-state forms and process parameters: Can increase development cost and timing.
• Bioequivalence strategy: Any requirement to match particle size, dissolution characteristics, or stability can become an IP constraint.

Which generic entry scenarios would cause the biggest revenue impact on DESCOVY?

In revenue terms, the largest impact typically comes from first meaningful generic replacement in PrEP programs where:

• formularies turn over quickly,
• state and large clinics switch from branded procurement,
• and patients convert at renewal.

Scenario A: Early generic approval with no effective marketing settlement

• Branded share drops rapidly in commercially insured and procurement channels.
• Net price collapses as competitors undercut branded WAC and contracting floors are renegotiated.

Scenario B: Settlement-driven “delayed launch” with shared market erosion

• Brand declines are less abrupt.
• Revenue decline becomes more gradual, linked to share and persistence drift before launch.

Scenario C: Partial market coverage due to label or patient population constraints

• Even with generic approval, coverage for certain patient groups can remain constrained by clinical guidance and payer policies.
• Revenue erosion becomes segmented by patient risk profile.

How does DESCOVY compare financially and commercially with competing TAF-based and TDF-based PrEP regimens?

TAF-based regimens usually target clinicians seeking improved renal and bone profiles. TDF-based generics often win on cost. Financially, DESCOVY’s trajectory depends on whether payers prioritize net cost after rebates or clinical differentiation.

Competitive cost per day and formulary placement

• TAF/FTC cost is higher than generic TDF/FTC absent favorable contracting.
• Formulary design often determines whether higher cost is accepted for renal-risk patients.

Switching and substitution behavior

• Where coverage mandates step therapy, substitution can be immediate.
• Without prior auth, switching depends on clinician preference and patient persistence.

What FDA regulatory pathway risks and opportunities matter for DESCOVY’s future?

FDA-related issues that can influence financial trajectory include:

• post-approval label changes affecting eligible populations,
• changes to dosing instructions,
• safety communications and adherence programs,
• and regulatory acceptance of new combinations or dosing in the same therapeutic class.

What would increase future revenue?

• Broader approved indications for PrEP populations that expand eligible patient counts.
• Evidence supporting additional use cases and increased clinician comfort.

What would reduce revenue?

• Safety or usage restrictions that constrain eligible patient groups.
• Increased scrutiny leading to lower adoption, more prior auth, or higher discontinuation.

Key Takeaways

• DESCOVY’s financial trajectory is driven by US PrEP persistence and formulary position, with payor contracting and channel inventory dynamics causing quarter-to-quarter volatility.
• The largest revenue downside risk is generic replacement driven by Orange Book patent expiry and Paragraph IV outcomes, with settlements often dictating real-world launch timing.
• Competitive pressure comes primarily from cost-driven substitution toward generic TDF/FTC, while DESCOVY differentiates through renal and bone-risk targeting when coverage allows.
• Near-term financial outcomes are most sensitive to US contracting terms, state and clinic procurement cycles, and the timing of any generic launch barriers falling away.

FAQs

1. What market events most quickly reduce DESCOVY net sales after patent expiry?
2. How do prior authorization and step-therapy rules change DESCOVY uptake in PrEP clinics?
3. What settlement terms typically control delayed generic launch timing for HIV fixed-dose combinations like DESCOVY?
4. How does generic substitution differ between commercially insured patients and state-funded PrEP programs?
5. What formulation or process patents most often delay ANDA launches even when core composition patents expire?

References

No sources were cited because no accessible, verifiable DESCOVY-specific financial, Orange Book, exclusivity, litigation, or patent docket data was provided in the prompt.

DrugChatter Q&A for DESCOVY

Descovy drug price in urguay?
Descovy loos of exclusivity in eu?
When does descovy patent expiry?
Descovy patent launch date?
Descovy generic availability 2026?